Skip to content

Organon OGN Other — Revenue

Similar metrics at other companies

Cabot Corporation logo
CBTOther Products And Services — Revenue
$4M-20.0%
Cleveland-Cliffs logo
CLFOther — Revenue
$617M+7.7%
AppFolio logo
APPFOther — Revenue
$2.63M-24.5%
Supernus Pharmaceuticals logo
SUPNOther — Total revenues
$4.67M-45.6%
SPS Commerce logo
SPSCOther — Revenue
$6.08M+1.4%
ePlus logo
PLUSOther Product — Revenue
$25.26M+782%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's other — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's other — revenue?
Organon (OGN) reported other — revenue of $18M in Q1 2026.
How has Organon's other — revenue changed year-over-year?
Organon's other — revenue decreased by 18.2% year-over-year, from $22M to $18M.
What is the long-term trend for Organon's other — revenue?
Over 4 years (2021 to 2025), Organon's other — revenue has grown at a -20.2% compound annual growth rate (CAGR), from $200M to $81M.
What does other — revenue mean?
This metric measures revenue generated from miscellaneous or ancillary products that fall outside the company's main product segments. It serves as a catch-all for secondary offerings that support the broader business model but are not central to the primary therapeutic focus. Tracking this metric provides insight into the company's ability to monetize non-core assets and manage a diverse product mix.